Day One Biopharmaceuticals’ (DAWN) Neutral Rating Reiterated at JPMorgan Chase & Co.

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “neutral” rating reiterated by JPMorgan Chase & Co. in a note issued to investors on Wednesday,Benzinga reports. They currently have a $21.50 price objective on the stock, down from their prior price objective of $27.00. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 0.92% from the stock’s previous close.

Several other research firms also recently weighed in on DAWN. HC Wainwright reaffirmed a “neutral” rating and set a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research note on Tuesday. JonesTrading cut Day One Biopharmaceuticals from a “buy” rating to a “hold” rating and increased their price objective for the stock from $20.00 to $21.50 in a research note on Friday, March 6th. TD Cowen downgraded Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Needham & Company LLC lowered Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a report on Friday. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $23.75.

Day One Biopharmaceuticals Stock Up 0.1%

DAWN stock traded up $0.03 during trading on Wednesday, hitting $21.31. The company had a trading volume of 1,538,818 shares, compared to its average volume of 4,546,947. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $21.43. The company has a 50 day simple moving average of $11.59 and a 200-day simple moving average of $9.28. The firm has a market capitalization of $2.20 billion, a P/E ratio of -20.68 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The company had revenue of $53.72 million during the quarter, compared to analysts’ expectations of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. Sell-side analysts forecast that Day One Biopharmaceuticals will post -0.72 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Michael Vasconcelles sold 2,728 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $31,644.80. Following the transaction, the insider directly owned 4,397 shares in the company, valued at approximately $51,005.20. This trade represents a 38.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Adam Dubow sold 6,395 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the transaction, the insider directly owned 72,694 shares in the company, valued at approximately $843,250.40. The trade was a 8.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in Day One Biopharmaceuticals by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after acquiring an additional 1,029 shares in the last quarter. Los Angeles Capital Management LLC raised its position in shares of Day One Biopharmaceuticals by 1.4% in the 4th quarter. Los Angeles Capital Management LLC now owns 100,314 shares of the company’s stock worth $935,000 after acquiring an additional 1,425 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of Day One Biopharmaceuticals by 2.1% in the 4th quarter. Perkins Capital Management Inc. now owns 84,000 shares of the company’s stock worth $783,000 after acquiring an additional 1,750 shares in the last quarter. CWM LLC lifted its stake in shares of Day One Biopharmaceuticals by 32.4% during the 4th quarter. CWM LLC now owns 8,373 shares of the company’s stock worth $78,000 after purchasing an additional 2,051 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Day One Biopharmaceuticals by 12.9% during the 2nd quarter. ProShare Advisors LLC now owns 18,545 shares of the company’s stock worth $121,000 after purchasing an additional 2,121 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.